Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.58 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 4/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231362 | 0.92 | MMP13 (0.52) | MMP13SLC22A8BCL2L11PDE1APDE1B | |
| SCHEMBL6233774 | 0.91 | MMP13 (0.52) | MMP13SLC22A8PDE1APDE1BPDE1C | |
| SCHEMBL6247434 | 0.90 | MMP13 (0.68) | MMP13SLC22A8 | |
| SCHEMBL6231376 | 0.83 | MMP13 (0.82) | MMP13SLC22A8POLBSMN1; SMN2DPP4 | |
| SCHEMBL6212954 | 0.83 | MMP13 (0.60) | MMP13SLC22A8PTGER4POLB | |
| SCHEMBL6229879 | 0.82 | MMP13 (0.55) | MMP13SLC22A8SMN1; SMN2 | |
| SCHEMBL15806029 | 0.81 | MMP13 (0.55) | MMP13SLC22A8 | |
| SCHEMBL6212989 | 0.78 | MMP13 (0.54) | MMP13PTGER4POLB | |
| SCHEMBL10021372 | 0.78 | MMP13 (0.61) | MMP13SLC22A8SMN1; SMN2 | |
| SCHEMBL6214058 | 0.77 | MMP13 (0.54) | MMP13SLC22A8PTGER4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | MMP13 2/4885SLC22A8 255/4885BCL2L11 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.